Amendment No. 1 to License Agreement between BioZone Pharmaceuticals, Inc. and BetaZone Laboratories LLC

Contract Categories: Intellectual Property › License Agreements
Summary

This amendment updates the original license agreement between BioZone Pharmaceuticals, Inc. (BPI), as successor to BioZone Laboratories, Inc., and BetaZone Laboratories LLC. BetaZone is allowed to keep making, marketing, and selling its current ophthalmic products under the agreement, including manufacturing rights. However, BetaZone is not permitted to develop, market, or sell any new ophthalmic products using confidential information or know-how from the agreement. The amendment is effective as of April 4, 2011.

Read More Arrow
EX-10.12 13 exhibit10_12.htm AMENDMENT NO. 1 TO LICENSE AGREEMENT exhibit10_12.htm  
 
Exhibit 10.12
 
 
AMENDMENT TO LICENSE AGREEMENT
 
This Amendment ("Amendment'"). effective as of ________, 2011. modifies the terms of the License Agreement ("Agreement") between BioZone Laboratories. Inc. and BetaZone Laboratories LLC dated November 7. 2006.
 
Whereas:
 
A.
BioZone Phamlaceutical. Inc .. a Delaware corporation having a principal place of business at 580 Garcia Avenue. Pittsburg. CA 94565 ("BPI") is the successor in interest to BioZone Laboratories. Inc. ("BU") and the assignee of the BLI’s entire interest under the Agreement:
 
B.
BetaZone Laboratories LLC ("BetaZone") has developed the ophthalmic products listed in the attached schedule ("Existing Ophthalmic Products") pursuant to the Agreement: and
 
C.
BLI wishes to enter into a new separate license agreement relating to ophthalmic products with a third party;
 
Therefore. BPI and BetaZone agree as follows.
 
1.
BetaZone shall have the right to continue to market and sell Existing Ophthalmic Products pursuant to the Agreement. Such right shall include all other rights necessary to implement such marketing and sales activity. including the right to continue manufacture of Existing Ophthalmic Products pursuant to the Agreement.
 
2.
BetaZone shall not develop. market or sell any new therapeutic and/or preventative ophthalmic products incorporating the confidential information and/or Know-How as defined in the Agreement.
 

 
Signed:
    
/s/ Camillo Rey
  
/s/ Brian Keller
Managing Director
  
CEO
BetaZone
  
BPI
     
04/04/2011
    
Date
  
Date